11 November 2020

COVIg for Immune Compromised Patients

SARS-CoV-2 is a new highly infectious respiratory virus. Although the disease, COVID-19, can be mild, people who are immune-compromised are particularly at high risk for severe disease progression. After mild symptoms such as fever and cough, severe dyspnoea may develop resulting in hospitalization. Often IC admission is required with artificial respiration. Ultimately, the situation may escalate to such an extent that multi-organ failure occurs requiring dialysis. Many people die due to multi-organ failure.
Cured patients have neutralizing antibodies against the SARS-CoV-2 virus in their blood plasma. These antibodies have the potential to be used therapeutically and prophylactically.

To arrive at a correct prioritization of patients, a working group from the transfusion medicine section has been set up that has drawn up guidelines for patient indication and the treatment with COVIg.

In the enclosed appendix you will find further information about indication and administration:

Indicatiestelling Hyperimmuun COVID-19 indicatie (in Dutch only)

 

Up